Commentary
Predicting the individual risk of NAFLD and determining the probability of disease progression is the basis for further developing prevention and treatment strategies. This requires knowledge of the genetic and epigenetic modifiers of NAFLD for genotype-guided risk stratification. This overview by W. Jonas and A. Schurmann (German Institute of Human Nutrition Potsdam-Rehbruecke, Germany) provides an insight into the genetic and epigenetic landscape of NAFLD.
Previous Post
A link between hyperuricemia and NAFLD
Next Post
Endolysosomal network and MAFLD